BlueCrest Capital Management
ECYT

BlueCrest Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

BlueCrest Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-171,019
Closed -$1.55M – 2046
2018
Q1 		$1.55M Buy
+171,019
New +$944K 0.05% 364
2017
Q3 		– Sell
-14,280
Closed -$21K – 1216
2017
Q2 		$21K Buy
+14,280
New +$30.7K ﹤0.01% 880

Other funds holding ECYT

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlueCrest Capital Management's ECYT Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 171,019 shares — an estimated $1.55M sold.

BlueCrest Capital Management first reported a position in ECYT in Q2 2017 and held it in 2 quarters. The position peaked at $1.55M in Q1 2018. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 171,019 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $1.55M.
  • BlueCrest Capital Management first reported a position in Endocyte, Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's Endocyte, Inc. Common Stock position peaked at $1.55M in Q1 2018.
  • 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.